8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 26, 2023)

Filed October 26, 2023For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 26, 2023, to announce its third-quarter 2023 financial results. The filing primarily includes a press release detailing these results and a related presentation shared during their earnings conference call. Investors should note that the company is referencing non-GAAP financial information, and reconciliations to GAAP measures are available in the furnished press release. While the specific financial figures are not detailed within this 8-K, the furnishing of the press release and presentation indicates that BMY has disclosed its Q3 performance and strategic updates. Investors are encouraged to review Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Bristol Myers Presentation) for the complete financial details, key performance indicators, and forward-looking statements.

Key Highlights

  • 1BMY released its Q3 2023 financial results on October 26, 2023, via an 8-K filing.
  • 2The filing includes the company's Q3 2023 Earnings Press Release (Exhibit 99.1).
  • 3A presentation on financial and operating initiatives (Exhibit 99.2) was also posted on the company's website and furnished with the filing.
  • 4The company is utilizing non-GAAP financial information in its reporting.
  • 5Reconciliations for non-GAAP to GAAP financial measures are provided within the Earnings Press Release (Exhibit 99.1).
  • 6The furnished information is not deemed 'filed' under Section 18 of the Exchange Act, but is provided for informational purposes under Regulation FD.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce Bristol-Myers Squibb's financial results for the third quarter of 2023 and to provide investors with access to the related press release and presentation materials.

The detailed financial results, including key performance indicators and management's commentary, are located in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are furnished as part of this 8-K filing.

Yes, Bristol-Myers Squibb is referencing non-GAAP financial information in its Q3 2023 results announcement. The filing states that reconciliations between these non-GAAP measures and the comparable GAAP financial measures are available in the Earnings Press Release (Exhibit 99.1).

As per the filing, the information furnished under Item 7.01 (Regulation FD Disclosure), including the press release and presentation, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into future filings. It is provided for disclosure purposes under Regulation FD.